



NDA 16-267/S-045

Novartis Pharmaceuticals Corporation
Attention: Anne Frederick, Ph.D.
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Frederick:

Please refer to your supplemental new drug application dated September 15, 2008, received September 15, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Desferal[®] (deferroxamine mesylate, USP) Injection.

This "Changes Being Effected" supplemental new drug application provides for correction of a typographical error found in the Dosage and Administration section, specifically Tables 1 and 3, "Preparation of Intramuscular Administration," of the label.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) and/or submitted labeling (package insert submitted September 15, 2008).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 16-267/S-045.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

NDA 16-267/S-045

Page 2

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Hyon-Zu Lee, Pharm.D., Regulatory Project Manager, at 301-796-2050.

Sincerely,

{See appended electronic signature page}

Rafel Dwaine Rieves, M.D.

Director

Division of Medical Imaging and Hematology Products

Office of Oncology Drug Products

Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Rafel Rieves

1/28/2009 11:17:32 AM